Quetiapine fumarate is initially approved by the FDA in 1997 and is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as Clozapine and Olanzapine. Quteklas (quetiapine fumarate) is a psychotropic agent belonging to a chemical class, the dibenzothiazepine derivatives.
Quetiapine Fumarate 25/50/100mg Tablet
MODE OF ACTION:
Although the mechanism of action of quetiapine is not fully understood, several proposed mechanisms exist. In schizophrenia, its actions could occur from the antagonism of dopamine type 2 (D2) and serotonin 2A (5HT2A) receptors. In bipolar depression and major depression, quetiapine’s actions may be attributed to the binding of this drug or its metabolite to the norepinephrine transporter. Additional effects of quetiapine, including somnolence, orthostatic hypotension, and anticholinergic effects, may result from the antagonism of H1 receptors, adrenergic α1 receptors, and muscarinic M1 receptors, respectively.
- Bipolar Disorder
- MDD in Adjunctive Therapy with Antidepressant
Recommended Adult Dosage
Adult: 150-750 mg/day, (Max: 750mg/day)
Children >12 Yrs. 400-600mg/day, (Max: 750mg/day)
This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.